1st Edition
SARS-CoV2 (COVID-19) Pandemic Control and Prevention An Epidemiological Perspective
This is the first comprehensive text to provide not only a detailed explanation of how the SARS-CoV2 (COVID-19) virus is spread within human populations, but also an epidemiological analysis and interpretation of viral pandemics to enable better measures for prevention and control.
Providing an introduction to the physiology of both the human immune system and the SARS-CoV2 virus, specifically the virus’s replicative potential and our own vulnerability, the book offers an in-depth understanding of how the pandemic evolved. It also highlights the aberrant epigenomic mechanistic process in pathogenic microbe’s replication and survival, implying gene and environment interaction that affected different populations. Citing a range of environmental conditions, from structural and systemic racism to malnutrition and low-socioeconomic status, the book examines how these factors exacerbated existing health disparities, resulting in a disproportionate burden of morbidity and mortality on certain social groups.
Also providing invaluable guidance on how future iterations of this pandemic may be better prevented and controlled, this will be a defining book for students, researchers and professionals within Public Health and Clinical Medicine to better understand the SARS-CoV2 (COVID-19) virus, and how to protect the most vulnerable social groups.
1.Immuno-epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno-epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS-CoV2 (COVID-19): Pandemic and Public Health Emergency Response. 4.SARS-CoV2 Mutation: Immuno-Epidemiologic and Socio-Epidemiologic Response. 5.COVID-19 Pandemic: Epidemic Curve Down-Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS-CoV2 Transmission & COVID-19 Fetal Survivability: Immuno-epidemiologic Perspective. 7.SARS-CoV2 (COVID-19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID-19 Pandemic Global Health Equity Transformation. 9.SARS-CoV2 "Re-emergence" as COVID-19 (2): Translational Public Health and Immuno-epidemiologic Response. 10.SARS-CoV2 (COVID-19) Viral Dynamics Control. 11.Immune System Senescence in SARS-CoV2 Transmission and COVID-19 Clinical Manifestations, Severity and Complications. 12.SARS-CoV2 Exponential Spread and COVID -19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS-CoV2 (COVID-19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS-CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS" and SARS-CoV2 (COVID-19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS-CoV2 (COVID-19) Novel Variants (DELTA), Vaccine Cross-effectiveness and Durability. 17.SARS-CoV2 (COVID-19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities-Blacks/African Americans (AA). 18.SARS-CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case-positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health-related Event in SARS-CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS-CoV2 (COVID-19) Vaccine Effectiveness and Durability in Immunogenic-related Comorbidities (Multiple Myeloma). 21.SARS-CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS-CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS-CoV2 (COVID-19) Morbidity Implication in Chronic Disease (Type II Diabetes –T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS-CoV2 (COVID-19) Pandemic resurgence: Epigenomic Public Health Perspective. 25.SARS-CoV2 (COVID-19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26.Black/African Americans (AA) and Disproportionate Burden of SARS-COV-2 (COVID-19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS-CoV2 and COVID-19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28.Racial/Ethnic and Geo-clustering Differentials in SARS-CoV-2 (COVID-19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA
Biography
Laurens (Larry) Holmes, Jr. is an immunologist and infectious disease specialist, and obtained his doctoral degree in cancer epidemiology and biostatistics from the University of Texas, Health Sciences Center at Houston. He is a Principal Translational Research Scientist, a former Founding Director of the Nemours Paediatric Translational Health Disparities Science research, training and education program, Wilmington, DE (USA), a leading proponent of epigenomic epidemiology in clinical medicine and public health and Affiliate professor of molecular epidemiology and clinical trials at the Biological Sciences Department at the University of Delaware, Newark, DE (USA), Co-founder and Director of Global Health Equity Foundation (GHEF-USA) and Founding Director of Lawhols International Scientific Research Consulting, LIS-RC (USA). Professor Holmes is currently a Director of the Graduate Public Health Program (Epidemiology and Global Health), Public Health & Allied Health Sciences Department, Wesley College-Delaware State University, Dover, DE (USA).
